Effectiveness of Medtronic CareLink Express System in identifying patients with high-energy electrotherapy devices requiring clinically significant intervention by Grabowski, Marcin et al.
Address for correspondence: Marcin Grabowski, MD, PhD, 1st Department of Cardiology, Medical University of Warsaw,  
ul. Banacha 1a, 02–097 Warszawa, Poland, tel: +48 22 65 82 997, fax: +48 22 59 91 957, e-mail: grabm@wum.edu.pl
Received: 30.04.2017 Accepted: 15.06.2017
Effectiveness of Medtronic CareLink Express  
System in identifying patients with high-energy 
electrotherapy devices requiring clinically  
significant intervention
Marcin Grabowski1, Sabina Sadecka1, Andrzej Cacko1, 2,  
Marcin Michalak1, Leszek Blicharz1, Paweł Balsam1, Grzegorz Opolski1
11st Department of Cardiology, Medical University of Warsaw, Poland 
2Department of Medical Informatics and Telemedicine, Medical University of Warsaw, Poland
Abstract
Background: The number of patients with implantable cardioverter-defibrillator (ICD) or cardiac 
resynchronization therapy and defibrillator (CRT-D) is growing. This results in high workloads for 
centers performing standard controls (SC) of these systems. Medtronic CareLink Express® (MCLE) is 
a solution enabling remote controls (RC) of implantable devices. In cases of detecting arrhythmias or 
device malfunctioning, it automatically generates alarms transmitted to the controlling physician. The 
objective of the study was to evaluate the effectiveness of alarms generated by MCLE in identification of 
patients that require clinically significant intervention during SC.
Methods: A total of 119 patients (age 64 ± 14, 17 women) implanted with ICD/CRT-D were included 
in the trial. Device reprogramming or pharmacological treatment modifications during SC were as-
sessed as significant if they were required for optimal clinical management of the patient (effectiveness 
of antiarrhythmic and resynchronization therapy, also patient safety). Analysis of generated alarms was 
then performed to assess the effectiveness (sensitivity and specificity) of MCLE in identifying patients 
that require changes in therapy.
Results: Data from 129 transmissions and 129 subsequent SCs were analyzed. 179 alarms were 
recorded during 96 (74%) transmissions. A total of 333 program changes of implanted devices took 
place during 107 (83%) SCs. Device reprogramming was considered clinically significant in 27 cases 
Additionaly, 13 pharmacological treatment modifications were performed. Sensitivity and specificity 
of alarms generated by MCLE with regards to identification of patients requiring clinically significant 
intervention was 87% and 31%, respectively. Finally, a statistically significant difference was observed 
in the number of clinically significant interventions among patients with and without MCLE alarms 
(33 [86.8%] vs. 5 [13.2%], p = 0.037).
Conclusions: Medtronic CareLink Express® is an RC system enabling high-sensitivity supervision of 
patients with cardiac electrotherapy devices requiring changes of treatment during SC. (Cardiol J 2018; 
25, 1: 81–86)
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Introduction
Recent years brought significant advancements 
in therapy of patients suffering from heart failure 
and concomitant arrhythmias [1, 2]. Implantable 
cardioverter-defibrillators (ICD) and cardiac re-
synchronization therapy and defibrillators (CRT-D) 
are now universally implemented in long-term 
prevention of cardiac arrest [3, 4]. An obvious 
downside associated with versatility of these high-
energy electrotherapy devices is the necessity to 
control them regularly so that their malfunctioning 
or deterioration of patients’ general state can be 
timely detected. Interventions performed during 
standard control (SC) include reprogramming of im-
planted device or adjustments of other clinical vari-
ables (e.g. pharmacological treatment) to optimize 
the therapy. These procedures increase workload 
in centers where SCs are performed. According 
to current standards, SC should be carried out at 
least once every 6–12 months in order to ensure 
appropriate clinical management of patients with 
a high-energy electrotherapy device [1]. Various re-
mote monitoring systems that enable self-controls 
of implantable devices have been created with 
capabilities of reducing the burden related with 
SCs. It is believed that remote controls (RC) hold 
the potential for decreasing frequency of SCs [5].
Medtronic CareLink Express® (MCLE) is 
a system available to patients managed by spe-
cialized centers performing SCs of implantable 
devices (Fig. 1). When MCLE detects arrhythmia 
or device malfunctioning during RC, it automati-
cally generates an alarm and transmits the data 
to the physician responsible for the follow-up of 
a given patient. Provided MCLE turns out to be 
a reliable remote monitoring system, it could limit 
the number of SCs and thus reduce the growing 
workload in control centers [6]. This could further 
encourage attempts to implement decision sup-
porting systems and artificial intelligence in clinical 
practice to increase efficiency of ambulatory care. 
The aim of the study was to evaluate the ef-
fectiveness of MCLE in identifying patients that re-
quire clinically significant intervention during SC.
Methods
Patients of a tertiary care center implanted 
with implantable cardioverter-defibrillator (ICD)/ 
/cardiac resynchronization therapy and defibrilla-
tor (CRT-D) were invited to take part in the trial. 
Refusal or inability to provide informed consent for 
personal and medical data collection in the MCLE 
system were adopted as exclusion criteria. All 
subjects presented for an in-person evaluation of 
the implanted device between April and December 
2013. 
Every patient was instructed on how to use 
MCLE and performed his/her first interrogation 
before SC took place.
Medtronic CareLink Express® enables trans-
mission of a wide range of information. The fol-
lowing data can be recorded during RCs performed 
with this system: current device programming, 
detected arrhythmic events, sensing and pacing 
parameters recorded in automatic tests, percent-
age of biventricular pacing (in case of CRT-D) 
and in some cases, assessment of heart failure 
compensation based on indirect criteria (mean 
physical activity, mean heart rate during the day 
and at night and transthoracic impedance). The 
data can be viewed in a Web browser immediately 
after transmission. Access to the data is secured 
with login and password. If a transmission contains 
information about the occurrence of arrhythmia or 
other anomalies detected by an implanted device, 
MCLE generates an alarm available to the user 
after logging in.
Medtronic CareLink Express® system is 
capable of generating automatic alarms reporting 
Figure 1. Medtronic CareLink Express system kit.
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the occurrence of sustained and non-sustained 
ventricular arrhythmias, supraventricular ar-
rhythmias, applied low- and high-energy anti-
arrhythmic interventions, decreased percentage 
of resynchronizing stimulation, reduced transtho-
racic impedance, increased pacing threshold and 
incorrect lead impedance in a low or high-energy 
circuit.
Every patient presented for SC directly after 
a transmission. Data such as detected arrhythmic 
events, malfunction of the implanted system, 
ICD/CRT-D reprogramming and pharmacological 
treatment changes were recorded in the patient’s 
history. Alarms generated by MCLE as well as 
all cases of device reprogramming or pharmaco-
therapy changes were analyzed. Changes made 
in device settings were divided into clinically 
significant and non-significant. Criteria of clini-
cal significance were fulfilled if reprogramming 
(1) concerned ventricular arrhythmia detection 
zone or antiarrhythmic therapy, discriminators of 
supraventricular arrhythmias, pacing mode, basic 
pacing rate and atrioventricular delay, and (2) was 
required for the effectiveness of antiarrhythmic 
and resynchronization therapy as well as for pa-
tient safety. Two experts analyzed the fulfilment 
of reprogramming criteria during each SC.
Data from transmissions via MCLE were 
then compiled with observations from subsequent 
SCs. Sensitivity and specificity of alarms gener-
ated by MCLE were analyzed to assess clinical 
usefulness of the system (i.e. ability to identify 
patients requiring clinically significant ICD/ 
/CRT-D reprogramming or medication changes 
during SC). 
This was achieved by comparing the rate of 
clinically significant reprogramming in patients 
with and without MCLE alarms. Statistical analysis 
was performed using Statistica 12. Differences 
between groups were analyzed with the c2 test. 
Statistically significant differences were defined 
with p £ 0.05.
Results
A total of 119 patients implanted with ICD/
CRT-D (101/18 respectively) were enrolled in the 
study from April 2013 to December 2013. Mean age 
of the study population was 64 ± 14 years (63 ± 14 
and 69 ± 12 for ICD and CRT-D group, respec-
tively). The majority of patients were males (86%). 
Mean time interval from device implantation to 
the assessed follow-up visit was 77 ± 58 weeks. 
Patient characteristics are presented in Table 1.
Data was analyzed from 129 consecutive 
MCLE transmissions (109 from ICD patients, 
20 from CRT-D patients), each RC was followed 
by a conventional in-person evaluation (SC). All 
patients managed to perform the transmission ow-
ing to a short course and a graphic manual.
179 event notifications were registered in 
96 (74.4%) transmissions (Fig. 2). Most reports 
concerned nonsustained ventricular tachycardia.
Device reprogramming was performed during 
100 (77.5 %) SCs. 333 changes were made in device 
settings (Fig. 3).
Table 1. Patients’ characteristics
Clinical factor Overall population 
(n = 119 pts)
ICD subgroup  
(n = 101 pts)
CRT-D subgroup   
(n = 18 pts)
Age [years] 64 ± 14 63 ± 14 69 ± 12
Males 102 (85.7%) 86 (85.1%) 16 (88.9%)
Time form device implantation [weeks] 77 ± 58 79 ± 52 64 ± 99
Primary prevention 99 (83.2%) 82 (81.2%) 17 (94.4%)
Data are shown as mean ± standard deviation or number (percentage); pts — patients
Figure 2. Medtronic CareLink Express® event notifica-
tions; NSVT — non-sustained ventricular tachycardia; 
VSE — ventricular sensing episode; VT/VF — ventricu-
lar tachycardia/ventricular fibrillation.
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Nevertheless, only 40 modifications (includ-
ing 27 device programming and 13 medication 
changes) in 38 SCs were clinically significant and 
necessary in terms of patient safety. These actions 
were utilized to assess the efficiency and safety. 
The conclusions were based on the sensitivity and 
specificity of the MCLE system.
Sensitivity of MCLE event notifications with 
regards to detection of a patient requiring clinically 
significant device reprogramming and/or changes in 
pharmacological treatment was 86.8%, specificity 
was 30.8% (positive and negative predictive value 
34.4% and 84.9%, respectively).
A statistically significant difference between 
the number of clinically significant interventions 
among patients with and without MCLE alarms 
was observed (33 [86.8%] vs. 5 [13.2%], p = 0.037) 
(Table 2).
Discussion
The number of implanted electrotherapy devic-
es is constantly rising both in Poland and in Europe 
[4]. This trend negatively affects physicians who 
manage patients after electrostimulation procedures 
creating an increased workload in control centers. 
The population with implanted ICD/CRT-D are at 
high risk of cardiovascular events and ventricular/
supraventricular arrhythmias [7, 8]. An improve-
ment of prognosis and quality of life requires alert-
ness and optimization of therapy. Adequate clinical 
management is essential for effective prevention 
of hospitalization, cardiovascular complications and 
progression of underlying disease.
Remote controls systems may be an answer to 
the increasing workload in cardiac electrotherapy 
centers. The benefits of RCs were proven in 
a series of clinical trials and include: reduction of 
inadequate interventions of an implanted device, 
lengthening of its working time and reduced inci-
dence of mortality and hospitalization [9–12]. RC 
systems can automatically generate alerts report-
ing arrhythmias or device malfunctioning. This 
information allows the electrophysiology team to 
identify patients requiring immediate changes in 
therapy [13–15].
Nevertheless, SCs remain necessary in the 
population of patients with implantable electro-
therapy devices [1, 2]. Current guidelines rec-
ommend SC at least once a year in subjects with 
a high-energy electrotherapy device. 
According to available research, this is the first 
European study to assess MCLE functionality in the 
optimization of the control process of ICD/CRT-D 
patients. Results of the trial suggest that MCLE 
may facilitate follow-up procedures in this group.
It must be stressed that MCLE has success-
fully enabled the identification of patients requiring 
clinically significant device reprogramming and 
changes in pharmacological treatment (sensitiv-
ity 86.8%; negative predictive value 84.9%). This 
clearly demonstrates that the use of MCLE system 
is safe due to its ability to indicate problematic 
patients. 
However, it is not possible to discriminate 
between patients that do and do not require a SC 
solely based on the generation of an MCLE alarm. 
Based on previous research regarding RC systems 
it is believed that there are some improvements 
which could increase the effectiveness of MCLE:
Table 2. Rate of clinically significant changes in device programing or pharmacotherapy among  
patients with and without Medtronic CareLink Express® (MCLE) event notifications.
Endpoint Patients with MCLE  
event notifications
Patients without MCLE 
event notifications
P
Significant device reprograming 23 (85.2%) 4 (14.8%) 0.149
Medication changes 1 (7.7%) 12; (92.3%) 0.119
Any clinically significant intervention 33 (86.8%) 5 (13.2%) 0.036
Figure 3. Device setting modifications.
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 — prioritization of automatic alarms — selec-
tion of MCLE alerts which were generated in 
emergency situations and require urgent SC;
 — elaboration of risk scales based on selected 
alarms and clinical parameters (patient clinical 
characteristics, physical examination);
 — creation of self-learning system capable of re-
al-time evaluation of transmissions via MCLE.
The aforementioned features could help ana-
lyze indications for SC and generate suggested 
proceeding based on potential benefits from device 
reprogramming or pharmacotherapy changes.
Medtronic CareLink Express® enables storage 
of detailed data about implanted device parameters, 
a patient’s clinical state, and information about the 
control process.
One cannot overestimate the beneficial influ-
ence of MCLE on a patients’ self-awareness. Suc-
cessive reports mention a wide range of difficulties 
patients have with implanted cardiac electrotherapy 
devices and experience during RCs performed with 
the help of Medtronic CareLink (MCL). In Tele 
HF trial, 14% of subjects belonging to the remote 
monitoring group did not perform a single transmis-
sion during the whole study [14]. An interesting and 
up-to-date analysis was also published in “Herz” by 
Siebermair et al. [16], who recorded the frequency 
of failure in performing a transmission via MCL 
and investigated the causes that led to the failure. 
A study group comprised of close to 160 subjects, 
24% did not register a single transmission during 
a 16-month observation. This situation took place 
despite at least two notifications sent to them by 
researchers. It is likely that this observation re-
sulted from patient non-compliance rather than from 
technical difficulties associated with transmissions. 
The non-compliance might have been caused by 
mental overload associated with MCL installation, 
insufficient engagement and cooperation of the 
physicians and fear for security of a patient’s per-
sonal data. Nevertheless, ambulatory interrogations 
via MCLE and MCL are identical to the ones per-
formed with the help of MCLE before the first SC 
in the present trial. The process of providing con-
sent for participation in the trial also looks similar. 
It seems that patients provided with MCLE cooper-
ate much better than patients using other systems, 
such as MCL.
Finally, it is worth mentioning that all patients 
showed a positive attitude toward MCLE register. 
A single, brief training on the station, in most 
situations carried out in the presence of at least 
one member of the family, was generally sufficient 
for independent execution of consecutive inter-
rogation. No patient refused to provide informed 
consent for participation in the MCLE register.
Limitations of the study
The main limitation of this study is that it pre-
sents the experience of a single center. MCLE is 
available in few cardiology units. According to avail-
able research, the presented clinic is the only one 
to have introduced MCLE in day-to-day monitoring 
of patients in Poland. SCs of the patients included in 
the trial were performed by one group of specialists 
following unified standards of implantable device 
programming. One investigator was responsible for 
teaching the patients how to perform a transmis-
sion via MCLE during the whole trial.
Conclusions
Medtronic CareLink Express® is a RC system 
designed for clinical supervision of patients with 
implanted cardiac electrotherapy devices. It en-
ables high-sensitivity identification of patients in 
need of clinically significant device reprogramming 
or changes in pharmacotherapy during an SC.
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